Scarica l'app Stockscreener
208.95
2.31%
4.71
Pre-mercato:
210.10
1.15
+0.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Citigroup Inc. Trims Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director sells $93k in stock - Investing.com India
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of Stock - MarketBeat
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
LGND Should I Buy - Intellectia AI
Decoding Ligand Pharmaceuticals Inc (LGND): A Strategic SWOT Ins - GuruFocus
Ligand Pharmaceuticals Files For Mixed Shelf Offering - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) files S-3 for $100M ATM offering with Leerink - Stock Titan
LIGAND PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for LGND, Maintains Outperform R - GuruFocus
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating - marketscreener.com
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Oppenheimer raises Ligand Pharma stock price target on royalty outlook By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Stifel reiterates Buy on Ligand Pharma stock, keeps $230 target - Investing.com Nigeria
Ligand Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, keeps $230 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highligh - GuruFocus
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Incorporated Reiterates Earnings Guidance for the Year 2026 - marketscreener.com
Ligand Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand (LGND) Surpasses Q4 Revenue Expectations with Robust Perf - GuruFocus
(LGND) Ligand Pharmaceuticals Expects 2026 Total Revenue Range $245M-$285M, vs. FactSet Est of $265.7M - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $8.00-$9.00, vs. FactSet Est of $8.42 - marketscreener.com
Ligand: Q4 Financial Results Overview - Bitget
Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Reports Q4 Revenue $59.7M, vs. FactSet Est of $55.6M - marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Posts Q4 Adjusted EPS $2.02 per Share, vs. FactSet Est of $1.50 - marketscreener.com
Ligand Pharmaceuticals Reports Strong Q4 and Full Year 2025 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
BRIEF-Ligand Pharmaceuticals Q4 EPS USD 2.12 - TradingView
Pharma group Ligand swings from loss to $124M profit as royalties jump - Stock Titan
Total debt per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
H.C. Wainwright Maintained Buy on Ligand (LGND) Feb 24, 2026 - Meyka
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00 at HC Wainwright - Defense World
Net current asset value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Free cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Total debt per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00 - MarketBeat
LGND Analyst Rating Update: HC Wainwright & Co. Raises Price Tar - GuruFocus
Ligand Pharmaceuticals IncorporatedEquity Right (LGNXZ) Price Target Increased by 68.71% to 0.00 - Nasdaq
State of New Jersey Common Pension Fund D Takes $2.40 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Envestnet Asset Management Inc. - Defense World
Volatility Watch: Is Ligand Pharmaceuticals Incorporated being accumulated by smart moneyPortfolio Gains Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Isthmus Partners LLC Sells 7,775 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Will Ligand Pharmaceuticals Incorporated stock deliver consistent dividendsBuy Signal & Intraday High Probability Setup Alerts - mfd.ru
Why Ligand Pharmaceuticals Incorporated stock is a must watch in 20252025 Top Decliners & Fast Moving Trade Plans - mfd.ru
Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Thursday - MarketBeat
MSN Money - MSN
Ligand (NASDAQ: LGND) CFO reports PSU and RSU vesting with tax-withheld shares - Stock Titan
Quarterly Earnings: Is Ligand Pharmaceuticals Incorporated in a bullish channel2025 Earnings Surprises & Free Reliable Trade Execution Plans - baoquankhu1.vn
This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge - The Motley Fool
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Public Sector Pension Investment Board Grows Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):